China Universal (Cayman) GP Limited is an investor involved in funding rounds such as the $102 million Series B for TOT BIOPHARM, a Chinese maker of anti-tumor drugs. The company is associated with China Universal, a domestic asset manager established in 2005, focusing on China-related assets.
Focus Areas
Notable Investments
